Which immunology drugs go off patent, and when?
13 blockbuster immunology drugs with about $86.4B in 2025 worldwide sales lose US exclusivity between 2025 and 2037, led by Dupixent (Sanofi / Regeneron, $17.8B). 3 lose it in 2025 or 2026; the biggest single year is 2031, with $23.0B.
2025 worldwide sales of each drug, placed in the year its first US generic or biosimilar can launch. Select a year for every drug going off patent that year.
| Drug | Company | US LOE | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Stelara | Johnson & Johnson | 2025 | $6.1B | Biosimilars launched | Copies on the US market | 2026 · −66% |
| Xolair | Roche / Novartis | 2026 | ≈$5.4B | Biosimilars launched | Copies on the US market | 2028 · pending |
| Simponi | Johnson & Johnson | 2026 | $2.7B | Company guidance | Approved, waiting to launch | – |
| Otezla | Amgen | 2028 | $2.3B | Settlement / court date | Approved, waiting to launch | 2027 · −65% |
| Cosentyx | Novartis | 2029 | $6.7B | Patent-expiry estimate | In clinical trials | 2028 · pending |
| Nucala | GSK | 2029 | ≈$2.6B | Patent-expiry estimate | In clinical trials | – |
| Enbrel | Amgen | 2029 | $2.2B | Settlement / court date | Approved, waiting to launch | 2026 · −67% |
| Taltz | Eli Lilly | 2030 | $3.6B | Company guidance | In clinical trials | – |
| Dupixent | Sanofi / Regeneron | 2031 | $17.8B | Company guidance | In clinical trials | – |
| Tremfya | Johnson & Johnson | 2031 | $5.2B | Company guidance | In clinical trials | – |
| Entyvio | Takeda | 2032 | ≈$6.0B | Company guidance | Filed with the FDA | 2028 · pending |
| Skyrizi | AbbVie | 2033 | $17.6B | Company guidance | No US filing found | – |
| Rinvoq | AbbVie | 2037 | $8.3B | Settlement / court date | Filed with the FDA | – |
Sorted by the year US exclusivity ends. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| AbbVie | Skyrizi and Rinvoq | $25.9B | 42% |
| Sanofi | Dupixent | ≈$17.8B | 36% |
| Johnson & Johnson | Stelara, Simponi and Tremfya | $13.9B | 15% |
| Novartis | Xolair and Cosentyx | $8.4B | 15% |
| Takeda | Entyvio | ≈$6.0B | 21% |
| Regeneron | Dupixent | $5.2B | 37% |
| Amgen | Otezla and Enbrel | $4.5B | 12% |
| Roche | Xolair | ≈$3.7B | 5% |
| Eli Lilly | Taltz | $3.6B | 5.5% |
| GSK | Nucala | ≈$2.6B | 6.1% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Stelara (2026, −66%), Xolair (2028, price pending), Otezla (2027, −65%), Cosentyx (2028, price pending), Enbrel (2026, −67%) and Entyvio (2028, price pending) were selected for Medicare price negotiation. See every negotiated Medicare price →